COTEMPLA XR-ODT Drug Patent Profile

When do Cotempla Xr-odt patents expire, and when can generic versions of Cotempla Xr-odt launch?

Cotempla Xr-odt is a drug marketed by Neos Theraps Inc and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has eight patent family members in five countries.

The generic ingredient in COTEMPLA XR-ODT is methylphenidate. There are thirty-two drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the methylphenidate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cotempla Xr-odt

A generic version of COTEMPLA XR-ODT was approved as methylphenidate by ACTAVIS ELIZABETH on June 19^th, 2020.

Summary for COTEMPLA XR-ODT

International Patents:	8
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	15
Patent Applications:	5,723
Drug Prices:	Drug price information for COTEMPLA XR-ODT
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for COTEMPLA XR-ODT
What excipients (inactive ingredients) are in COTEMPLA XR-ODT?	COTEMPLA XR-ODT excipients list
DailyMed Link:	COTEMPLA XR-ODT at DailyMed

See drug prices for COTEMPLA XR-ODT

Pharmacology for COTEMPLA XR-ODT

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Paragraph IV (Patent) Challenges for COTEMPLA XR-ODT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
COTEMPLA XR-ODT	Extended-release Orally Disintegrating Tablets	methylphenidate	8.6 mg, 17.3 mg and 25.9 mg	205489	1	2017-09-01

US Patents and Regulatory Information for COTEMPLA XR-ODT

COTEMPLA XR-ODT is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-001	Jun 19, 2017	AB	RX	Yes	No	11,166,947
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-002	Jun 19, 2017	AB	RX	Yes	No	8,840,924		Y
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-001	Jun 19, 2017	AB	RX	Yes	No	8,840,924		Y

Expired US Patents for COTEMPLA XR-ODT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-001	Jun 19, 2017	8,840,924
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-003	Jun 19, 2017	8,840,924
Neos Theraps Inc	COTEMPLA XR-ODT	methylphenidate	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	205489-002	Jun 19, 2017	8,840,924

International Patents for COTEMPLA XR-ODT

When does loss-of-exclusivity occur for COTEMPLA XR-ODT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering COTEMPLA XR-ODT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2017353921	Effective dosing of a child for the treatment of ADHD with methylphenidate
European Patent Office	3585439	DOSAGE EFFICACE D'UN ENFANT POUR LE TRAITEMENT DU TDAH AVEC DU MÉTHYLPHÉNIDATE (EFFECTIVE DOSING OF A CHILD FOR THE TREATMENT OF ADHD WITH METHYLPHENIDATE)
Japan	2020504763	メチルフェニデートを用いてＡＤＨＤを処置するための小児の有効な投薬

Last updated: July 29, 2026

Cotempla XR-ODT Market Dynamics and Financial Trajectory: Sales Drivers, Price, Competitive Threat, and Exclusivity Timeline

Cotempla XR-ODT (cotempla min/amphetamine extended-release orally disintegrating tablet) is an expanded-release methylphenidate product in the ADHD market whose near- to mid-term financial trajectory is governed by (1) stimulant market share shifts across ER formulations and dosage forms, (2) payer contracting and rebates versus other ER methylphenidates, (3) generic and authorized-generic entry risk, and (4) Orange Book and litigation outcomes that determine whether branded supply is forced out or price pressure accelerates.

Key point: the dominant financial swing factors are not pure demand growth but channel economics and substitution behavior. In stimulants, formulary placement, step therapy, prior authorization, and net price after rebates largely determine realized revenue. On the IP side, the practical risk is earlier-than-expected generic/AB-rated product access if patent and exclusivity barriers are weak or expire sooner than the market expects.

What is Cotempla XR-ODT’s commercial profile in the ADHD stimulant market?

Cotempla XR-ODT is positioned for patients needing ER methylphenidate with an orally disintegrating tablet (ODT) or “easy administration” attribute. In ADHD, treatment adherence and caregiver administration convenience affect persistence and switching, but payers typically treat ER methylphenidate products as therapeutically substitutable within class.

Commercial drivers that move revenue

• Formulary access: managed-care contracting that changes net price and volume.
• Substitution pressure: strong within-class switching among ER methylphenidates and between methylphenidate and amphetamine ER products depending on formulary.
• Dosing flexibility and titration: clinician ability to match symptom control to dosing schedule.
• Supply reliability: stimulant product shortages can temporarily boost competitor demand, or vice versa.

Channel reality in stimulants

• Realized revenue is usually a function of net price, not list price. Net price is shaped by rebates and discounting tied to formulary status and volume.
• ODT-specific convenience can support differentiation, but payer contracting usually dominates.

How do payer dynamics shape Cotempla XR-ODT pricing and net sales?

Payer behavior in ADHD ER stimulants tends to follow a repeatable pattern: if a brand is not the preferred ER methylphenidate option, net price compresses quickly through contracting, rebates, and restrictions like prior authorization.

Net sales levers

• Contract tier placement (preferred vs non-preferred).
• Formulary rules for step edits from IR to ER or between ER products.
• State Medicaid preferred drug lists and behavior on ODT coverage.
• Pharmacy benefit manager (PBM) incentives that reward formulary compliance.

What that means for financial trajectory

• Short-term revenue can hold if Cotempla XR-ODT maintains preferred status or retains a high-convenience segment.
• Medium-term revenue is vulnerable if competitors add market-moving dosing strengths, improved coverage, or aggressive discounting.

What exclusivity and patent timelines control Cotempla XR-ODT’s sales ceiling?

Sales ceiling risk is driven by the timing of:

1. regulatory exclusivity (e.g., new chemical entity or other exclusivities as applicable),
2. Orange Book patent expiration and any pediatric exclusivity adjustments, and
3. the date of generic launch or authorized generic entry under Hatch-Waxman.

How exclusivity translates to revenue

• If patents and exclusivities remain intact through a given year, revenue typically declines more slowly.
• If a key Orange Book patent falls earlier, competitive entry can cause a discrete revenue step-down.

Practical implication

• In stimulants, even when only part of the product line is protected (specific strengths, dosage forms, or specific polymorph/formulation attributes), generic pressure can still appear across the portfolio due to payer switching.

What is the Orange Book status of Cotempla XR-ODT and which patents are most sale-relevant?

The sale-relevant patents are the ones that cover:

• the extended-release oral dosage form itself,
• specific formulation technologies or release-control compositions,
• method-of-use claims that protect the labeled therapeutic regimen.

Featured-snippet answer (what to look for)

• Identify the Orange Book listings tied to the exact NDA for Cotempla XR-ODT and then isolate the “last-to-expire” listed patents that claim the relevant extended-release and ODT features.

Why this matters

• If the last expiring patent is formulation or method-of-use, generic risk may be slower and dependent on carve-outs.
• If the last expiring patent is narrow to a specific technical aspect that is easy to design around, launch risk increases.

When does Cotempla XR-ODT lose exclusivity and how fast can generic erosion occur?

Generic erosion in ER ADHD stimulants can be rapid when:

• an ANDA receives approval with an AB rating for the listed FDA reference product, and
• payers switch quickly to lower net cost equivalents.

Typical erosion profile in stimulants

• Early phase: volume shifts after formulary updates, often within 1-2 quarters post-approval where contracting permits.
• Middle phase: net price compression accelerates; brands lose preferred position as soon as PBMs add generics to favored tiers.
• Late phase: remaining premium usually depends on patient switching frictions, prescriber preference in specific subgroups, and caregiver preference for ODT.

Financial trajectory impact

• If generic entry is late in the exclusivity window, revenue holds longer but then declines faster in the post-launch period.
• If generic entry risk grows earlier through litigation outcomes, brands often start discounting and rebate enhancements before launch, which still depresses net sales.

What generic entry risks exist for Cotempla XR-ODT (including Paragraph IV)?

Paragraph IV filings indicate challengers believe at least one Orange Book patent is invalid and/or not infringed. The economic consequence is twofold:

• a potential “design-around” and launch threat that can begin after litigation,
• market expectation of erosion that can change contracting decisions and purchasing behavior even before final outcomes.

Market mechanism

• If challenger litigation progresses, brands may increase payer engagement and rebate spending, which reduces margin even if launch does not immediately occur.
• If a settlement enables an earlier-than-expected launch, net sales can fall faster than exclusivity-only models predict.

Which companies are likely competitors to Cotempla XR-ODT and how do they compare on market position?

Cotempla XR-ODT competes in ER methylphenidate and adjacent stimulant classes. In practice, competitive intensity comes from multiple directions:

• ER methylphenidate brands and authorized generics
• ER amphetamine products that can win coverage through different clinical positioning
• ODT alternatives, if any, within the class

What comparative advantage means commercially

• If Cotempla XR-ODT keeps meaningful payer preference through convenience-based differentiation, it can retain higher net price than peers.
• If competitive ER tablets or capsules become preferred, ODT advantage reduces to niche coverage and limited share.

Revenue sensitivity

• In stimulants, share loss often correlates more with payer preference than with therapeutic superiority.

How does Cotempla XR-ODT compare with other ER methylphenidate products on competitive headwinds?

The competitive landscape is usually dominated by ER methylphenidate formulary choices. The strongest comparisons for a revenue trajectory view include:

• whether competitors are preferred in major PBM formularies,
• whether competitors have multiple dose strengths that enable easier titration,
• whether competitors have better access after step therapy.

What the comparison should test

• Net price and rebate competitiveness after formulary changes.
• Launch timing of competitor generics and any settlement that shifts launch dates.
• Differences in administration convenience affecting adherence and persistence.

What patent litigation and settlement dynamics matter for Cotempla XR-ODT revenue?

Stimulant branded revenue typically depends on whether:

• litigation results in stays that delay ANDA approval,
• settlements provide “no-early-launch” commitments through a stated date,
• court decisions narrow or invalidate key Orange Book patents.

Financial linkage

• If litigation leads to a clear early launch date, revenue declines start before launch due to payer anticipation.
• If litigation blocks launch for an extended period, revenue decline can be smoother and mostly driven by contracting and substitution rather than abrupt generic entry.

What regulatory milestones and FDA status affect commercialization timing?

For revenue trajectory, FDA timing matters mainly through:

• ANDA approval and labeling that matches the reference product AB rating,
• changes in supply allocation or manufacturing approvals that can affect fill rates.

Commercial impact

• If FDA actions restrict manufacturing or label changes force switching behavior, revenue can swing.
• Conversely, manufacturing stability supports consistent volume and reduces “stock-out” driven share volatility.

How do manufacturing and formulation IP barriers affect generic launch speed?

In ER stimulant products, generic launch speed is tied to the ability to match:

• release profiles (pharmacokinetics),
• ODT or ER-specific formulation characteristics that support bioequivalence.

Barriers that slow launch

• complex ER formulation requirements,
• difficult scale-up and stability constraints,
• additional patents on formulation technologies.

Barriers that accelerate launch

• narrow patents that are easily designed around,
• challengers with prior platform technology for ER stimulants.

What is the expected revenue path under multiple generic launch scenarios?

Revenue paths can be modeled as discrete events driven by:

• Orange Book expiration and final litigation outcomes,
• ANDA approval date,
• payer implementation of formulary tier and substitution.

Scenario framework

1. No generic launch through end of key patent window: gradual erosion driven by contracting and within-class substitution.
2. Generic launch after core patents expire but before additional formulation protection ends: mid-speed erosion with partial volume retention among convenience-driven patients.
3. Early launch due to adverse litigation or earlier settlement: sharp revenue step-down and margin compression.

Key Takeaways

• Cotempla XR-ODT’s financial trajectory is primarily shaped by stimulant channel economics: formulary placement, step edits, rebates, and switching dynamics across ER methylphenidates and amphetamine products.
• The IP clock that matters is the Orange Book “last-to-expire” protection that covers the exact ER ODT dosage form and any sale-relevant formulation or method-of-use claims.
• Generic entry risk, especially where Paragraph IV challenges and litigation settlements determine launch timing, is the main driver of abrupt revenue declines.
• Manufacturing and formulation-specific barriers can slow generic entry even when some patents expire, but payer substitution behavior can still compress net price quickly post-approval.

FAQs

1) What drives net price changes for ER ADHD stimulants like Cotempla XR-ODT?
Formulary tiering, rebate structures, PBM contracting, and prior authorization or step therapy rules.

2) How do Paragraph IV filings typically affect branded stimulant sales before a generic actually launches?
Market anticipation changes payer behavior and contracting, often leading to earlier rebate increases and preferred-position shifts.

3) Do ODT-specific attributes materially delay generic substitution in ADHD ER stimulants?
They can support patient-level persistence, but payer substitution and AB-rated interchange usually dominate unless coverage is restrictive.

4) What types of patents most influence generic launch timing for ER stimulant products?
Formulation and release-control patents tied to the protected extended-release dosage form, plus any sale-relevant method-of-use claims.

5) How can litigation outcomes create revenue dips independent of patent expiration?
Settlements and court rulings can set earlier effective launch dates or reduce the remaining patent runway, prompting payer contracting shifts.

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
2. FDA. Hatch-Waxman Drug Patent Certifications and Paragraph IV. FDA.
3. FDA. Drug Approval Process and Exclusivity. FDA.